Post-treatment Neurocognition and Psychosocial Care Among Breast Cancer Survivors

American Journal of Preventive Medicine

Volumn 49, Issue 6, 2015, Pages S498-S508

  Buchanan, Natasha D ^a   Dasari, Sabitha ^b   Rodriguez, Juan L ^a   Lee Smith, Judith ^a   Hodgson, M Elizabeth ^c   Weinberg, Clarice R ^d   Sandler, Dale P ^d  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b NORTHROP GRUMMAN CORPORATION   (United States)

^c SOCIAL AND SCIENTIFIC SYSTEMS INC   (United States)

^d NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; ATTENTION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER SURVIVOR; CANCER THERAPY; COGNITION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD; PSYCHOLOGIC TEST; PSYCHOSOCIAL CARE; RECALL; SELF REPORT; SHORT TERM MEMORY; ADJUVANT CHEMOTHERAPY; ADVERSE EFFECTS; BREAST NEOPLASMS; CHEMICALLY INDUCED; COGNITION DISORDERS; DOCTOR PATIENT RELATION; DRUG EFFECTS; HEALTH SERVICE; MIDDLE AGED; PSYCHOLOGY; QUESTIONNAIRE; SURVIVOR; VERY ELDERLY;

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COGNITION; COGNITION DISORDERS; FEMALE; HEALTH SERVICES; HUMANS; MIDDLE AGED; PHYSICIAN-PATIENT RELATIONS; SURVEYS AND QUESTIONNAIRES; SURVIVORS;

EID: 84983535064     PISSN: 07493797     EISSN: 18732607     Source Type: Journal    
DOI: 10.1016/j.amepre.2015.08.013     Document Type: Article

References (36)

1. 1 Janelsins, M.C., Kohli, S., Mohile, S.G., Usuki, K., Ahles, T.A., Morrow, G.R., An update on cancer- and chemotherapy-related cognitive dysfunction: current status. Semin Oncol 38:3 (2011), 431–438, 10.1053/j.seminoncol.2011.03.014.
2. 2 Wefel, J.S., Vardy, J., Ahles, T., Schagen, S.B., International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol 12:7 (2011), 703–708, 10.1016/S1470-2045(10)70294-1.
3. 3 Wefel, J.S., Saleeba, A.K., Buzdar, A.U., Meyers, C.A., Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer 116:14 (2010), 3348–3356, 10.1002/cncr.25098.
4. 4 Castellon, S.A., Ganz, P.A., Bower, J.E., Petersen, L., Abraham, L., Greendale, G.A., Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J Clin Exp Neuropsychol 26:7 (2004), 955–969, 10.1080/13803390490510905.
5. 5 Schilder, C.M., Eggens, P.C., Seynaeve, C., et al. Neuropsychological functioning in postmenopausal breast cancer patients treated with tamoxifen or exemestane after AC-chemotherapy: cross-sectional findings from the neuropsychological TEAM-side study. Acta Oncol 48:1 (2009), 76–85, 10.1080/02841860802314738.
6. 6 Boele, F.W., Schilder, C.M., de Roode, M.L., Deijen, J.B., Schagen, S.B., Cognitive functioning during long-term tamoxifen treatment in postmenopausal women with breast cancer. Menopause 22:1 (2015), 17–25, 10.1097/GME.0000000000000271.
7. 7 Schilder CM, Seynaeve C, Linn SC, et al. Self-reported cognitive functioning in postmenopausal breast cancer patients before and during endocrine treatment: findings from the neuropsychological TEAM side-study. Psychooncology. 2012;21(5):479–487. http://dx.doi.org/10.1002/pon.1928.
8. 8 Schilder CM, Seynaeve C, Beex LV, et al. Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the Tamoxifen and Exemestane Adjuvant Multinational trial. J Clin Oncol. 2010;28(8):1294–1300. 10.1200/JCO.2008.21.3553.
9. 9 Forsythe, L.P., Kent, E.E., Weaver, K., et al. Receipt of psychosocial care among cancer survivors in the United States. J Clin Oncol 31:16 (2013), 1961–1969, 10.1200/JCO.2012.46.2101.
10. 10 Buchanan, N., King, J., White, A., et al. Cancer survivorship trends: comparing findings from the 1992 and 2010 National Health Interview Survey. ISRN Oncol, 2013, 2013, 238017, 10.1155/2013/238017.
11. 11 Hewitt M, Breen N, Devesa S. Cancer prevalence and survivorship issue: analyses of the 1992 National Health Interview Survey. J Natl Cancer Inst. 1991;91:1480–1486. http://dx.doi.org/10.1093/jnci/91.17.1480.
12. 12 D׳Aloisio, A.A., DeRoo, L.A., Baird, D.D., Weinberg, C.R., Sandler, D.P., Prenatal and infant exposures and age at menarche. Epidemiology 24:2 (2013), 277–284, 10.1097/EDE.0b013e31828062b7.
13. 13 Fei, C., DeRoo, L.A., Sandler, D.P., Weinberg, C.R., Fertility drugs and young-onset breast cancer: results from the Two Sister Study. J Natl Cancer Inst 104:13 (2012), 1021–1027, 10.1093/jnci/djs255.
14. 14 Weinberg, C.R., Shore, D.L., Umbach, D.M., Sandler, D.P., Using risk-based sampling to enrich cohorts for endpoints, genes, and exposures. Am J Epidemiol 166:4 (2007), 447–455, 10.1093/aje/kwm097.
15. 15 NHIS. National Health Interview Survey, CDC; 2011. www.cdc.gov/nchs/nhis/nhis_questionnaires.htm.
16. 16 Yabroff, K.R., Dowling, E., Rodriguez, J., et al. The Medical Expenditure Panel Survey (MEPS) experiences with cancer survivorship supplement. J Cancer Surviv 6:4 (2012), 407–419, 10.1007/s11764-012-0221-2.
17. 17 Cancer SAQ pretest reports for 2011 survey year. http://meps.ahrq.gov/mepsweb/survey_comp/cncr_prtst_report_2011.shtml. Published 2014.
18. 18 FACIT Measurement System. FACT Cognitive Functioning Scale. (Cella D, tech. ed.). www.facit.org/FACITOrg/Questionnaires. Published 2015.
19. 19 Patient-Reported Outcomes Measurement Information System. www.nihpromis.org/?AspxAutoDetectCookieSupport=1#4. Published 2015.
20. 20 Jim, H.S., Phillips, K.M., Chait, S., et al. Meta-analysis of cognitive functioning in breast cancer survivors previously treated with standard-dose chemotherapy. J Clin Oncol 30:29 (2012), 3578–3587, 10.1200/JCO.2011.39.5640.
21. 21 Buwalda, B., Schagen, S.B., Is basic research providing answers if adjuvant anti-estrogen treatment of breast cancer can induce cognitive impairment. Life Sci 93:17 (2013), 581–588, 10.1016/j.lfs.2012.12.012.
22. 22 Sherwin, B.B., Estrogen and cognitive functioning in women: lessons we have learned. Behav Neurosci 126:1 (2012), 123–127, 10.1037/a0025539.
23. 23 Deary, I.J., Corley, J., Gow, A.J., et al. Age-associated cognitive decline. Br Med Bull 92:1 (2009), 135–152, 10.1093/bmb/ldp033.
24. 24 Thome, S.E., Bultz, B.D., Baile, W.F., SCRN Communication Team. Is there a cost to poor communication in cancer care? A critical review of the literature. Psychooncology 14:10 (2005), 875–884, 10.1002/pon.947.
25. 25 Leaf, P.J., Bruce, M.L., Tischler, G.L., Holzer, C.E., The relationship between demographic factors and attitudes toward mental health services. J Community Psychol 15:2 (1987), 275–284, 10.1002/1520-6629(198704)15:2<275::AID-JCOP2290150216>3.0.CO;2-J.
26. 26 Tijhuis, M.A., Peters, L., Foets, M., An orientation toward help-seeking for emotional problems. Soc Sci Med 31:9 (1990), 989–995, 10.1016/0277-9536(90)90108-5.
27. 27 Gonzalez, J.M., Alegria, M., Prihoda, T.J., Copeland, L.A., Zeber, J.E., How the relationship of attitudes toward mental health treatment and service use differs by age, gender, ethnicity/race and education. Soc Psychiatry Epidemiol 46:1 (2011), 45–57, 10.1007/s00127-009-0168-4.
28. 28 Meichenbaum, D., Teaching thinking: a cognitive-behavioral perspective. Chipman, S.F., Segal, J.W., Glaser, R., (eds.) Thinking and Learning Skills, Vol. 2: Research and Open Questions, 1985, Lawrence Erlbaum Associates, Hillsdale, NJ.
29. 29 IOM. Cancer Care for the Whole Patient: Meeting Psychosocial Health Needs. Adler, N.E., Page, A.E.K., (eds.), 2008, National Academies Press, Washington, DC.
30. 30 Myers, J.S., A comparison of the theory of unpleasant symptoms and the conceptual model of chemotherapy-related changes in cognitive function. Oncol Nurs Forum 36:1 (2009), E1–E10, 10.1188/09.ONF.E1-E10.
31. 31 Evens, K., Eschiti, V.S., Cognitive effects of cancer treatment: “Chemo Brain” explained. Clin J Oncol Nurs 13:6 (2009), 661–666, 10.1188/09.CJON.661-666.
32. 32 Nelson, C.J., Nandy, N., Roth, A.J., Chemotherapy and cognitive deficits: mechanisms, findings, and potential interventions. Palliat Support Care 5:3 (2007), 273–280, 10.1017/S1478951507000442.
33. 33 Staat, K., Segatore, M., The phenomenon of chemo brain. Clin J Oncol Nurs 9:6 (2005), 713–721, 10.1188/05.CJON.713-721.
34. 34 Shelli, K., Hadi Hosseini, S.M., Heckler, C., et al. Cognitive training for improving executive function in chemotherapy-treated breast cancer survivors. Clin Breast Cancer 13:4 (2013), 299–306, 10.1016/j.clbc.2013.02.004.
35. 35 Von Ah, D., Habermann, B., Carpenter, J.S., Schneider, B.L., Impact of perceived cognitive impairment in breast cancer survivors. Eur J Oncol Nurs 17:2 (2013), 236–241, 10.1016/j.ejon.2012.06.002.
36. 36 Myers, J.S., Chemotherapy-related cognitive impairment: the breast cancer experience. Oncol Nurs Forum 39:1 (2012), E31–E40, 10.1188/12.ONF.E31-E40.